Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
F Cappuzzo, T Ciuleanu, L Stelmakh… - The Lancet …, 2010 - europepmc.org
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2010 - infona.pl
First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is usually limited
to four to six cycles. Maintenance therapy can delay progression and prolong survival. The …
to four to six cycles. Maintenance therapy can delay progression and prolong survival. The …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2010 - Elsevier
BACKGROUND: First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC)
is usually limited to four to six cycles. Maintenance therapy can delay progression and …
is usually limited to four to six cycles. Maintenance therapy can delay progression and …
[引用][C] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh… - The Lancet …, 2010 - digibuo.uniovi.es
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre,
randomised, placebo-controlled phase 3 study RUO Principal Repositorio Institucional de la …
randomised, placebo-controlled phase 3 study RUO Principal Repositorio Institucional de la …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh… - The Lancet …, 2010 - pubmed.ncbi.nlm.nih.gov
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The Lancet …, 2010 - elibrary.ru
The study was sponsored by F Hoffmann-La Roche and medical writing support was
provided by Rhiannon Owen of Gardiner-Caldwell Communications; this support was …
provided by Rhiannon Owen of Gardiner-Caldwell Communications; this support was …
[PDF][PDF] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh… - Lancet …, 2010 - mauriciolema.webhost4life.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
[PDF][PDF] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - Lancet Oncol, 2010 - academia.edu
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …